Australia Respiratory Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The australia respiratory devices market size is projected to be USD 268.26 million in 2025, USD 283.14 million in 2026, and reach USD 370.94 million by 2031, growing at a CAGR of 5.55% from 2026 to 2031. This report is Segmented by Device Type (Diagnostic and Monitoring Devices, Therapeutic Devices, and Disposables), End-User (Hospitals & Clinics, Home Healthcare Settings, and More), Disease Indication (COPD, Asthma, and More), and Age Group (Adult, Geriatric, Pediatric). The Market Forecasts are Provided in Terms of Value (USD).

Australia Respiratory Devices Market Trends and Insights

Increasing Prevalence of Chronic Respiratory Disorders

Australia continues to face a heavy respiratory disease burden that keeps both diagnostic and therapeutic equipment in steady use across care settings. COPD prevalence rises sharply with age, reaching 7.0% among those 65 and older compared to 2.5% nationally, which concentrates utilization among older cohorts and supports sustained replacement cycles for spirometers, oxygen therapy, and ventilatory support. Underdiagnosis remains a recognized challenge, underscoring the role of primary care spirometry and remote monitoring in closing gaps in detection and long-term management. Disparities in COPD prevalence create a policy case for targeted access programs and procurement models that reduce up-front barriers to therapy in underserved communities. National clinical guidance updates introduced in late 2024 are intended to improve diagnosis quality and care consistency, which typically increases test volumes and drives a more standardized approach to device selection in hospitals and clinics. As Australia’s median age rises, these clinical and demographic dynamics support durable demand for connected devices that can alert care teams to deteriorations earlier and help prevent avoidable admissions.

Government Investment in Respiratory Clinics & Home-Care Programs

Federal funding is locking in the shift toward virtual and community-based respiratory care, reducing strain on tertiary hospitals. The 2025-26 Budget allocates AUD 8.5 billion (USD 5.7 billion) to strengthen Medicare, including sustained support for telehealth items that keep respiratory consultations and at-home follow-up viable at scale. The budget also funds a national lung cancer screening program over four years, which is expected to increase the use of spirometry and related diagnostic equipment across primary and specialist pathways. The National Disability Insurance Scheme received AUD 175.4 million (USD 117 million) in additional appropriations that improve access to assistive technology for eligible participants who require home ventilators and portable oxygen systems. State initiatives that embed remote monitoring into chronic care pathways have shown promise in reducing avoidable admissions for COPD, which encourages broader payor and provider adoption of connected respiratory devices. This public investment environment favors suppliers that can meet TGA requirements and align product roadmaps with care models designed around telehealth, home titration, and proactive disease management.

High Upfront Cost of Advanced Devices

High acquisition costs for advanced devices make access uneven across income bands and geographies, especially when home-use equipment lacks a consistent public subsidy. While hospital procurement can amortize capital over multi-year cycles, patients who require personal CPAP or portable oxygen for home use face meaningful out-of-pocket exposure and variable private insurance coverage. Regulatory fee schedules also flow into end-user pricing and distributor margins, since manufacturers pass through TGA cost-recovery charges that scale with application complexity. Tiered application fees create hurdles for smaller suppliers of low-volume specialty devices, which can limit competition in narrow subcategories where clinical needs are acute. As a result, procurement teams and providers weigh the total cost of ownership and service reliability when choosing between premium connected platforms and more basic alternatives. The Australia respiratory devices market continues to benefit from telehealth-driven efficiency, but affordability barriers temper the pace of penetration in segments that rely on self-funding.

Other drivers and restraints analyzed in the detailed report include:

• Technological Advances in Connected Respiratory Devices
• Shift Toward Home-Based Sleep-Apnea & COPD Management
• Stringent Post-Market Surveillance & UDI Compliance

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic devices commanded 48.67% of the Australia respiratory devices market size in 2025, reflecting the central role of CPAP and BiPAP platforms in sleep-disordered breathing and chronic respiratory care. This dominance is reinforced by the ongoing adoption of connected CPAP systems that enable remote titration, nightly adherence tracking, and rapid clinical interventions for therapy adjustment. Disposables are the fastest-growing category, with an 8.80% CAGR through 2031, as infection prevention teams codify single-use practices across ICUs and sleep labs, which increases pull-through for circuits, masks, bacterial filters, and humidification accessories. Nebulizers remain essential for acute management of asthma and COPD exacerbations, with mesh technology gaining share due to quieter operation, rapid aerosol delivery, and better acceptance among children and older adults. Oxygen concentrators benefit from overlapping demand drivers that include COPD progression among older Australians and seasonal smoke or infection surges that spike needs for ambulatory oxygen support. Smart inhalers that incorporate counters and connectivity are expanding in chronic use cases where adherence gaps and technique errors have historically driven preventable exacerbations. Together, these factors keep the therapeutic, disposable, and monitoring subcategories aligned with the connectivity trend that now defines leadership in the Australia respiratory devices market.

Hospitals and clinics held a 61.05% share of the Australia respiratory devices market in 2025, as high-acuity ventilators, anesthesia workstations, and polysomnography systems remain anchored in inpatient and specialist settings. These facilities also standardize on integrated monitoring that pulls vital signs and respiratory data into centralized platforms, which creates switching costs that favor established device ecosystems. At the same time, home healthcare is growing at a 10.40% CAGR through 2031 as permanent Medicare telehealth items support remote consultations, CPAP titration, and virtual follow-up for stable chronic conditions. This tilt toward the home opens opportunities for remote setup, digital adherence support, and proactive troubleshooting by vendors and providers. Ambulatory surgical centers increase the adoption of portable anesthesia and basic respiratory monitoring for day procedures, although clinical scope rules limit the complexity of cases managed outside hospitals. Aged-care operators are raising device density per bed, given the growth in residents with COPD and chronic heart failure, and they prefer options that integrate with electronic medication records to streamline workflows.

Complete Report Scope:

• By Device Type
  • Diagnostic & Monitoring Devices
    • Spirometers
    • Sleep Test Devices
    • Peak Flow Meters
    • Pulse Oximeters
    • Capnographs
    • Other Diagnostic & Monitoring
  • Therapeutic Devices
    • CPAP Devices
    • BiPAP Devices
    • Humidifiers
    • Nebulizers
    • Oxygen Concentrators
    • Ventilators
    • Inhalers
    • Other Therapeutic Devices
  • Disposables
    • Masks
    • Breathing Circuits
    • Other Disposables
• By End-User
  • Hospitals & Clinics
  • Home Healthcare Settings
  • Ambulatory Surgical Centers
  • Others
• By Disease Indication
  • COPD
  • Asthma
  • Sleep Apnea
  • Pneumonia & Acute Respiratory Infections
  • Others
• By Age
  • Adults
  • Geriatric
  • Pediatric

List of Companies Covered in this Report:

• 3M
• AirPhysio Pty Ltd
• Asahi Kasei Corp. (ZOLL Medical)
• Chart Industries
• Dragerwerk
• Drive DeVilbiss Healthcare
• Fisher & Paykel Healthcare
• GE Healthcare Technologies Inc.
• Getinge
• Hamilton Medical
• Inogen Inc.
• Invacare
• Koninklijke Philips
• Masimo
• Medtronic
• Nihon Kohden
• Resmed
• Teleflex
• Vyaire Medical
• Xefco Pty Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support